NovoCure Q1 2023 Earnings Report $30.51 +0.66 (+2.21%) (As of 12/3/2024 06:07 PM ET) NovoCure EPS ResultsActual EPS-$0.50Consensus EPS -$0.36Beat/MissMissed by -$0.14One Year Ago EPS-$0.04NovoCure Revenue ResultsActual Revenue$122.20 millionExpected Revenue$127.93 millionBeat/MissMissed by -$5.73 millionYoY Revenue Growth-11.10%NovoCure Announcement DetailsQuarterQ1 2023Date5/4/2023TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseSEC FilingNVCR Earnings HistorySlide DeckFull Screen Slide DeckPowered by The Biggest Financial Event of 2024? (Ad)Should you buy, sell, or hold your stock? To find the answer, let’s look at the actions of the world’s wealthiest investors… Right now, the world’s wealthiest investors are preparing for what could become ‘the biggest financial event’ of 2024.Click here for the step-by-step details NovoCure Earnings HeadlinesNovoCure (NASDAQ:NVCR) Raised to Outperform at Evercore ISIDecember 4 at 3:15 AM | americanbankingnews.comNovocure seeks approval after pancreatic cancer wearable scores at Phase IIIDecember 4 at 2:38 AM | msn.comWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.December 4, 2024 | Behind the Markets (Ad)NovoCure’s PANOVA-3 Trial Success Boosts Oncology ProspectsDecember 3 at 2:26 AM | markets.businessinsider.comWedbush Reiterates Neutral Rating for NovoCure (NASDAQ:NVCR)December 3 at 1:30 AM | americanbankingnews.comNovocure Stock Soars On Positive Pancreatic Cancer Trial Results, Retail Sentiment SurgesDecember 2 at 3:57 PM | msn.comSee More NovoCure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NovoCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NovoCure and other key companies, straight to your email. Email Address About NovoCureNovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.View NovoCure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report Upcoming Earnings Toronto-Dominion Bank (12/5/2024)Canadian Imperial Bank of Commerce (12/5/2024)Bank of Montreal (12/5/2024)Oracle (12/9/2024)Adobe (12/11/2024)Broadcom (12/12/2024)Costco Wholesale (12/12/2024)Accenture (12/17/2024)Micron Technology (12/18/2024)Paychex (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
